MedTrace Logo

Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization

NCT00479895 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2008-05-30

No results posted yet for this study

Summary

The test compound and subject of this clinical trial is the haemoglobin-based oxygen carrier, HBOC-201 (Hemopure). HBOC-201, initially developed as an alternative to red blood cells for surgical patients, has the ability to restore tissue oxygenation in persistently ischemic tissue. The development of this new class of compounds, referred to as oxygen therapeutics, provides an opportunity to test the safety and efficacy of a new approach to management of myocardial ischemia.

Conditions

  • Coronary Occlusion
  • Acute Coronary Syndrome

Interventions

DRUG

Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)

Pre-oxygenated HBOC-201

Sponsors & Collaborators

  • Biopure Corporation

    lead INDUSTRY

Principal Investigators

  • A. Gerson Greenburg, MD, PhD · Biopure Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-03-31
Completion
2008-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00479895 on ClinicalTrials.gov